{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:09:12Z","timestamp":1777727352624,"version":"3.51.4"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,8,15]]},"DOI":"10.2169\/internalmedicine.4467-20","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T22:07:08Z","timestamp":1588889228000},"page":"2041-2045","source":"Crossref","is-referenced-by-count":9,"title":["Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin"],"prefix":"10.2169","volume":"59","author":[{"given":"Atsushi","family":"Isoda","sequence":"first","affiliation":[{"name":"Department of Hematology, National Hospital Organization Shibukawa Medical Center, Japan"},{"name":"Department of Hematology, Hoshi Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Shibukawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Shibukawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Mihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Shibukawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Shibukawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Shibukawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Sawamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Shibukawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Means RT Jr. Pure red cell aplasia. Blood 128: 2504-2509, 2016.","DOI":"10.1182\/blood-2016-05-717140"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Davis EJ, Salem JE, Young A, et al. Hematologic complications of immune checkpoint inhibitors. Oncologist 24: 584-588, 2019.","DOI":"10.1634\/theoncologist.2018-0574"},{"key":"3","unstructured":"3. Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6: e48-e57, 2019."},{"key":"4","unstructured":"4. Mizobuchi S, Yamashiro T, Nonami Y, et al. Pure red cell aplasia and myasthenia gravis with thymoma: a case report and review of the literature. Jpn J Clin Oncol 28: 696-701, 1998."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Handgretinger R, Geiselhart A, Moris A, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 340: 278-284, 1999.","DOI":"10.1056\/NEJM199901283400405"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Masuda M, Saitoh H, Mizoguchi H. Clonality of acquired primary pure red cell aplasia. Am J Hematol 62: 193-195, 1999.","DOI":"10.1002\/(SICI)1096-8652(199911)62:3<193::AID-AJH10>3.0.CO;2-D"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Clauvel JP, Vainchenker W, Herrera A, et al. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol 55: 380-382, 1983.","DOI":"10.1111\/j.1365-2141.1983.tb01260.x"},{"key":"8","unstructured":"8. Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin-a report of eight patients. Am J Hematol 61: 16-20, 1999."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Song KW, Mollee P, Patterson B, Brien W, Crump M. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 119: 125-127, 2002.","DOI":"10.1046\/j.1365-2141.2002.03778.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 58: 1351-1353, 2009.","DOI":"10.1007\/s00262-008-0627-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med 374: 1096-1097, 2016.","DOI":"10.1056\/NEJMc1509362"},{"key":"12","unstructured":"12. Suzuki A, Takahashi T, Taniguchi A, et al. Pure red cell aplasia associated with non-Hodgkin&apos;s lymphoma and hemolytic anemia. Jpn J Clin Oncol 21: 384-387, 1991."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Katayama H, Takeuchi M, Yoshino T, et al. Epstein-Barr virus associated diffuse large B-cell lymphoma complicated by autoimmune hemolytic anemia and pure red cell aplasia. Leuk Lymphoma 42: 539-542, 2001.","DOI":"10.3109\/10428190109064614"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Assimakopoulos SF, Michalopoulou S, Melachrinou M, et al. Primary Sj\u00f6gren syndrome complicated by autoimmune hemolytic anemia and pure red cell aplasia. Am J Med Sci 334: 493-496, 2007.","DOI":"10.1097\/MAJ.0b013e318068b5fd"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hara A, Wada T, Kitajima S, et al. Combined pure red cell aplasia and autoimmune hemolytic anemia in systemic lupus erythematosus with anti-erythropoietin autoantibodies. Am J Hematol 83: 750-752, 2008.","DOI":"10.1002\/ajh.21241"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755, 2001.","DOI":"10.1056\/NEJMra993360"},{"key":"17","unstructured":"17. Bystryn JC, Rudolph JL. IVIg treatment of pemphigus: how it works and how to use it. J Invest Dermatol 125: 1093-1098, 2005."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bj\u00f6rkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med 234: 119-126, 1993.","DOI":"10.1111\/j.1365-2796.1993.tb00720.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 14: 152-161, 2013.","DOI":"10.1038\/ni.2496"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Thibult ML, Mamessier E, Gertner-Dardenne J, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 25: 129-137, 2013.","DOI":"10.1093\/intimm\/dxs098"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28: 583-589, 2017.","DOI":"10.1093\/annonc\/mdw640"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100: 105-113, 2019.","DOI":"10.1016\/j.jaut.2019.03.005"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Crusz SM, Radunovic A, Shepherd S, et al. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Eur J Cancer 102: 49-51, 2018.","DOI":"10.1016\/j.ejca.2018.07.125"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hasanov M, Konoplev SN, Hernandez CMR. Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. Blood Adv 2: 1865-1868, 2018.","DOI":"10.1182\/bloodadvances.2018019000"},{"key":"25","unstructured":"25. Khan U, Ali F, Khurram MS, Zaka A, Hadid T. Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer. Forthcoming."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Gokozan HN, Friedman JD, Schmaier AH, et al. Acquired hemophilia A after nivolumab therapy in a patient with metastatic squamous cell carcinoma of the lung successfully managed with rituximab. Clin Lung Cancer 20: e560-e563, 2019.","DOI":"10.1016\/j.cllc.2019.06.022"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4467-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T03:20:18Z","timestamp":1597461618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4467-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4467-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}